The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance

American Journal of Medicine

Volumn 100, Issue 6, 1996, Pages 617-623

  Nguyen, M Hong ^a   Peacock Jr , James E ^b   Morris, Arthur J ^c   Tanner, David C ^c   Nguyen, Minh Ly ^a   Snydman, David R ^d   Wagener, Marilyn M ^a   Rinaldi, Michael G ^e   Yu, Victor L ^a,f  

^a VA Healthcare VISN 4   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CALCULATION; CANDIDA ALBICANS; CANDIDIASIS; DISEASE CONTROL; DOSE RESPONSE; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; TORULOPSIS GLABRATA;

EID: 0345340404     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(95)00010-0     Document Type: Article

References (37)

1. 1. Edwards JR, Jr. Invasive Candida infections. Evolution of a fungal pathogen. N Engl J Med. 1991;324:1060-1062.
2. 2. Beck-Sague CM, Jarvis WR, the National Nosocomial Infectious Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 1993;167:1247-1251.
3. 3. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642-2645.
4. 4. Wey SB, Mori M, Pfaller MA, Woolson RA, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med. 1989;149:2349-2353.
5. 5. Dyess DL, Garrison N, Fry DE. Candida species. Implications of polymicrobial blood-borne infection. Arch Surg. 1985;120:345-348.
6. 6. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992:15:414-421.
7. 7. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 1985;7:646-655.
8. 8. Klein JJ, Watanakunakorn C. Hospital-acquired fungemia. Its natural course and clinical significance. Am J Med. 1979:67:51-58.
9. 9. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrate in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989:3:379-390.
10. 10. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med. 1981;71:363-370.
11. 11. Nielsen H, Stenderup J, Bruun B. Fungemia in a university hospital 1984-1988. Scand J Infect Dis. 1991;23:275-282.
12. 12. Young RC, Bennett JE, Geelhoed GW, Levine AS. Fungemia with compromised host resistance. Ann Intern Med. 1974:80:605-612.
13. 13. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 1991;325:1274-1315.
14. 14. Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW. Fluconazole and Candida krusei fungemia (Letter). N Engl J Med. 1991;325:1315.
15. 15. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-851.
16. 16. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med. 1993;118:495-503.
17. 17. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: proposed standard. NCCLS document M27-P 1992;12:1-21.
18. 18. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia; evaluation in a multicenter, prospective observational study. Arch Intern Med. 1995;155:2429-2435.
19. 19. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood culture over a 5-year period. Antimicrob Agents Chemother. 1994;38:1422-424.
20. 20. Berkowitz ID, Robboy SJ, Karchmer AW, Kunz LJ. Torulopsis glabrata fungemia: a clinical pathological study. Medicine. 1979;58:430-440.
21. 21. Pappagianis D, Collins MS, Hector R, Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother. 1979;16:123-126.
22. 22. Merz WG, Sandford GR. Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol. 1979;9:677-680.
23. 23. Guinet R, Ghanas J, Goullier A, Bonnefoy G, Ambroise-Thomas P. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J Clin Microbiol. 1983;18:433-444.
24. 24. Nguyen MH, Morris AJ, Dobson ME, Snydman DR, Peacock JE, Jr, Rinaldi MG, Yu VL. Candida lusitaniae: an important emerging cause of candidemía. Occurrence during a prospective fungemia study. Infect Dis Clin Prac. 1996; in press.
25. 25. Rex JH, Bennett JE, Sugar AM. A randomized trial comparing fluconazole with amphotericin B for the treatment in patients without neutropenia. N Engl J Med. 1994;331:1325-1330.
26. 26. Pfaller MA, Rhine-Chalberg J, Redding SW, Smith J, Farinacci G, Fothergill AW, Rinaldi MG. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients in AIDS and oral candidiasis. J Clin Microbiol. 1994; 32:59-64.
27. 27. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type I. Antimicrob Agents Chemother. 1993;37:2449-2453.
28. 28. Sandven P, Bjorneklett A, Maeland A, the Norwegian Yeast Study Group. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob Agents Chemother. 1993;37:2443-2448.
29. 29. Willocks L, Leen CLS, Brettle RP, Urquhart D, Russell TB, Milne LJR. Fluconazole resistance in AIDS patients. J Antimicrob Chemother. 1991;28:937-939.
30. 30. Fox R, Neal KR, Leen CLS, Ellis ME, Mandal BK. Fluconazole resistant Candida in AIDS. J infect. 1991;22:201-204.
31. 31. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994;97:339-346.
32. 32. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1980;18:158-163.
33. 33. Dick JD, Rosengard BR, Merz WG, Stuart RK, Hutchins GM, Saral R. Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Ann Intern Med. 1985;102:67-68.
34. 34. Fan-Havard P, Capano D, Smith SM, Mangia A, Eng RHK. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991;35:2302-2305.
35. 35. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988;84:826-832.
36. 36. Bodenhoff J. Resistance studies of Candida albicans, with special reference to two patients subjected to prolonged antimycotic treatment. Odontol Tidskr. 1968;76:279-294.
37. 37. Eubanks PJ, deVirgilio C, Klein S, Bongard F. Candida sepsis in surgical patients. Am J Surg. 1993;166:617-620.